Orthopedic Bone Cement Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Material (Polymethyl Methacrylate (PMMA), Ceramic, Acrylic, Others), By Product Type (Low Viscosity Cements, Medium Viscosity Cements, High Viscosity Cements, Antibiotic Cements), By End-User (Hospitals, Orthopedic Clinics and Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 819.11 Million
CAGR (2026-2031)	6.16%
Fastest Growing Segment	Hospitals
Largest Market	North America
Market Size (2031)	USD 1172.49 Million

Market Overview

The Global Orthopedic Bone Cement Market is projected to grow from USD 819.11 Million in 2025 to USD 1172.49 Million by 2031 at a 6.16% CAGR. Orthopedic bone cement is a polymethyl methacrylate grouting material utilized to anchor prosthetic implants to the underlying bone during joint replacement surgeries. The market is primarily supported by an expanding geriatric population and a rising prevalence of osteoarthritis which necessitates frequent arthroplasty interventions. According to the American Joint Replacement Registry, in 2025, the registry recorded an 8.8% increase in total procedural volume compared to the previous year, confirming the escalating demand for surgical interventions. Additionally, high rates of trauma and sports injuries further drive the consistent requirement for effective fixation solutions in healthcare systems.

One significant challenge impeding market expansion is the increasing preference for cementless implants which utilize biological fixation instead of grouting agents. This alternative is particularly favored in younger patients and North American markets which directly reduces cement utilization in primary procedures. Consequently, manufacturers face competitive pressure from biological fixation technologies which limits the addressable market for traditional cementing products.

Key Market Drivers

The rising prevalence of osteoarthritis and osteoporosis is a primary determinant of market trajectory, fundamentally increasing the patient pool requiring cemented fixation. As bone density deteriorates, surgeons increasingly rely on polymethyl methacrylate (PMMA) cement to ensure immediate and stable implant anchorage, particularly in elderly cohorts where biological or cementless integration is often compromised. This reliance is intensified by the sheer burden of skeletal fragility which necessitates frequent surgical intervention. According to the International Osteoporosis Foundation, October 2024, in the 'World Osteoporosis Day' press release, up to 37 million fragility fractures occur annually worldwide in individuals aged over 55, underscoring the critical need for reliable fixation solutions in fracture management and reconstructive procedures. Consequently, healthcare systems are compelled to maintain substantial inventories of bone cement to address the high incidence of fragility-related arthroplasty.

Concurrently, the surge in the volume of joint replacement and arthroplasty surgeries is acting as a direct catalyst for product consumption. The expansion of surgical eligibility to include younger, active patients and the clearing of procedural backlogs have intensified the frequency of knee and hip interventions utilizing cemented techniques. According to Stryker, October 2024, in the 'Q3 2024 Earnings Call', the company experienced robust demand with its U.S. knee business growing 8.4% organically, reflecting the broader escalation in procedural throughput. This operational momentum is visible across the wider sector, driving consistent revenue gains for fixation technologies. According to Smith+Nephew, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', the Orthopaedics business unit delivered an underlying revenue growth of 6.0%, confirming the sustained commercial expansion of the joint reconstruction market and the associated demand for cementing agents.

Download Free Sample Report

Key Market Challenges

The primary challenge hindering market growth is the accelerating shift toward cementless implants, which utilize biological fixation rather than PMMA grouting agents. This trend fundamentally restricts the market because it removes the necessity for bone cement in a growing proportion of joint replacement procedures. As surgeons increasingly prioritize press-fit implants that promote natural bone ingrowth—particularly for younger patients with better bone quality—the total addressable volume for cementing products is significantly reduced. This preference effectively bypasses the bone cement market for primary interventions, forcing manufacturers to rely more heavily on the revision market or older demographic segments.

This erosion of market share is substantiated by recent industry data. According to the American Joint Replacement Registry, in its 2024 Annual Report, cementless fixation in primary total knee arthroplasties accounted for approximately 22% of all procedures recorded in 2023, reflecting a continued year-over-year increase. The steady rise of biological fixation in the knee segment, which was traditionally a stronghold for cemented solutions, demonstrates a direct displacement of bone cement usage. This sustained migration toward cementless technologies limits revenue potential and creates a long-term structural barrier for traditional bone cement suppliers.

Key Market Trends

The increasing adoption of antibiotic-loaded bone cements for infection prophylaxis has become a dominant trend as healthcare providers prioritize the reduction of periprosthetic joint infections (PJI). Surgeons are widely standardizing the use of antimicrobial-impregnated fixatives in primary and revision arthroplasty to mitigate the high economic and clinical costs associated with septic failures. This prophylactic strategy is now firmly established in clinical practice across major global markets, driven by the need to protect implants from bacterial colonization immediately post-implantation. According to JAMA Network Open, May 2024, in the 'Periprosthetic Joint Infection After Total Knee Arthroplasty' study, an analysis of international registry data revealed that 93% of the 2.1 million primary total knee arthroplasties reviewed were performed utilizing antibiotic-loaded bone cement.

Concurrently, there is a rising preference for high-viscosity cements which offer superior handling characteristics essential for modern minimally invasive surgery (MIS) techniques. These formulations provide immediate stability and controlled application, reducing the risk of cement leakage into surrounding tissues while allowing for more precise pressurization in restricted surgical fields. Manufacturers are responding to this demand by developing advanced high-viscosity products that also incorporate dual-antibiotic agents to address complex resistance profiles without compromising mechanical integrity. According to Heraeus Medical, August 2024, in the 'Press Release', the company launched the COPAL G+V bone cement which features a high-viscosity formulation containing a specific combination of 0.5 grams of gentamicin and 2.0 grams of vancomycin per unit to support stable fixation and infection management.

Segmental Insights

The Hospitals segment is currently identified as the fastest growing category within the Global Orthopedic Bone Cement Market, primarily driven by the increasing volume of complex joint reconstruction and trauma surgeries. Market analysis indicates that while outpatient settings are evolving, hospitals remain the essential environment for high-risk procedures and revision arthroplasties that require intensive post-operative monitoring. Furthermore, the rapid expansion of public healthcare infrastructure in emerging economies heavily favors hospital-based settings to accommodate rising patient caseloads. This sustained necessity for comprehensive clinical capabilities positions hospitals as the primary accelerator of market demand.

Regional Insights

North America dominates the global orthopedic bone cement market, primarily driven by the high volume of joint reconstruction surgeries performed across the region. This leadership is sustained by a growing aging population susceptible to osteoarthritis, which necessitates frequent orthopedic interventions. Additionally, the region benefits from established healthcare reimbursement frameworks that facilitate patient access to these procedures. The presence of key medical manufacturers, coupled with rigorous product oversight by the United States Food and Drug Administration, ensures a consistent supply chain and maintains high safety standards, thereby reinforcing North America’s position as the primary regional market.

Recent Developments

• In August 2024, Heraeus Medical announced the commercial launch of its COPAL G+V bone cement in the United States following clearance from the U.S. Food and Drug Administration. This high-viscosity bone cement was formulated with a combination of two antibiotics, gentamicin and vancomycin, to support the treatment of periprosthetic joint infections. The launch aimed to provide orthopedic surgeons with a pre-mixed, dual-antibiotic solution that ensured homogenous antibiotic dispersion and retained mechanical strength. The company emphasized that this product addition strengthened its infection management portfolio and addressed the clinical need for effective antimicrobial protection in revision arthroplasty procedures.
• In July 2024, Tecres entered into a strategic partnership with Wiltrom to expand the distribution of spinal augmentation solutions across Europe. Through this collaboration, the company agreed to distribute the Tripod-Fix Vertebral Body Augmentation System in key markets including Spain, Poland, and Switzerland. This alliance aimed to combine the company's established expertise in bone cement and preformed spacers with the partner's specialized spinal fixation technologies. The collaboration was designed to enhance the portfolio of orthopedic solutions available to European surgeons, particularly for treating vertebral compression fractures and other spinal conditions requiring bone cement augmentation.
• In May 2024, OsteoRemedies LLC announced that it obtained clearance from the U.S. Food and Drug Administration for expanded indications of its Spectrum GV bone cement. The regulatory body approved the dual antibiotic-loaded bone cement, which contains both gentamicin and vancomycin, for use in component fixation during revision total hip arthroplasty procedures. This expanded indication also covered two-stage revision surgeries following initial infections. The company highlighted that this approval provided surgeons with a critical tool for managing complex revision cases where high concentrations of antibiotics are required to address infection risks effectively within the orthopedic sector.
• In March 2024, BoneSupport AB received 510(k) clearance from the U.S. Food and Drug Administration for its antibiotic-eluting bone void filler, CERAMENT G. This regulatory approval allowed the company to market the product for use in bone defects in the extremities of skeletally mature patients. The clearance indicated that the product could be used as an adjunct to systemic antibiotic therapy and surgical debridement for managing bone infections. This development was significant for the Global Orthopedic Bone Cement Market as it offered a resorbable ceramic substitute capable of eluting gentamicin to protect bone healing and effectively reduce the risk of infection recurrence.

Key Market Players

• Stryker Corporation
• Smith & Nephew PLC
• Johnson & Johnson Services, Inc.
• Zimmer Biomet Holdings, Inc.
• Subiton LABORATORIOS SL S.A
• DJO Global Inc.
• Arthrex Inc.
• Tecres SpA
• Synimed SARL

By Material	By Product Type	By End-User	By Region
Polymethyl Methacrylate (PMMA) Ceramic Acrylic Others	Low Viscosity Cements Medium Viscosity Cements High Viscosity Cements Antibiotic Cements	Hospitals Orthopedic Clinics and Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Orthopedic Bone Cement Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Orthopedic Bone Cement Market, By Material:

• Polymethyl Methacrylate (PMMA)
• Ceramic
• Acrylic
• Others

• Orthopedic Bone Cement Market, By Product Type:

• Low Viscosity Cements
• Medium Viscosity Cements
• High Viscosity Cements
• Antibiotic Cements

• Orthopedic Bone Cement Market, By End-User:

• Hospitals
• Orthopedic Clinics and Centers
• Others

• Orthopedic Bone Cement Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE